What Is Evolysse™? The First FDA-Approved HA Filler in a Decade

What is Evolysse? The first FDA-approved HA filler in a decade

In February 2025, the first new hyaluronic acid filler in ten years received FDA approval.

That matters. In medicine, a gap like that usually means existing options are already strong. The bar is high. Regulatory bodies do not approve new products simply because they are new. Something gets approved when the evidence is compelling enough to clear a very high standard and when it offers something the existing options do not.

So I went straight to the data.

I want to walk you through what I found: what Cold-X technology actually is, what the clinical trial showed, and what this means for patients considering dermal fillers in Maidstone.

Why hyaluronic acid crosslinking matters

Before we get to Evolysse specifically, it helps to understand the problem it is trying to solve.

Hyaluronic acid occurs naturally throughout the body. It is a sugar molecule with a remarkable capacity for water retention and in the skin it provides both hydration and structural support. On its own, however, injectable hyaluronic acid breaks down within days. To make it last long enough to be clinically useful, it has to be crosslinked: chemically bonded into a gel structure that resists enzymatic breakdown.

Here's the thing. How you crosslink the HA determines everything about the final product: its firmness, its softness, how it integrates with surrounding tissue, how long it lasts, and how natural the result looks and feels. Traditional crosslinking is performed at elevated temperatures and high pH using a crosslinking agent called BDDE. That caustic, heated environment does what it needs to do. But it also causes fragmentation of the longer HA chains, which may affect both the structure and the longevity of the gel.

Cold-X technology crosslinks at near-freezing temperatures, between 0°C and 10°C. The lower temperature better preserves the longer HA chains, requires less BDDE to achieve the same structural properties, and reduces fragmentation. The result, in theory, is a filler that more closely preserves the natural HA architecture.

The theory is sound. But in my cardiac nursing days I learned that theory without clinical data is just a hypothesis. What matters is what actually happens in patients, measured against a rigorous comparator. So let me tell you what the trial showed.

What the pivotal study actually found

The pivotal study for Evolysse Form and Evolysse Smooth was a randomised, controlled, double-blind split-face trial published in the Aesthetic Surgery Journal in July 2025. It enrolled 140 patients with moderate-to-severe nasolabial folds. Each patient received an Evolysse product on one nasolabial fold and Restylane-L, one of the most established hyaluronic acid fillers available, on the other. Patients were then followed for 12 months.

The split-face design is worth pausing on because it is methodologically important. Same patient. Same skin. Same age. Same sun exposure. Same genetics. The only variable between the two sides was which product was used. It is one of the most rigorous study designs in filler research precisely because it eliminates almost all confounders. When you see a difference in a well-executed split-face trial, you can be confident the product is responsible for it.

Both products met the primary endpoint of non-inferiority to Restylane-L. And then, on several measures, they went further.

Evolysse Form showed statistically significant improvement over Restylane-L at every single measured timepoint across the full 12-month study period, as assessed by live, blinded investigators. That consistency across a full year is clinically meaningful.

Evolysse Smooth showed statistically significant improvement over Restylane-L at six and nine months. The detail that caught my attention most: Evolysse Smooth achieved those superior results while using approximately 20% less product than the Restylane-L control group required. Less product. Better outcomes. That suggests efficient tissue integration rather than simply greater volume, which is exactly what Cold-X technology was designed to achieve.

On safety, the profile of both Evolysse products was comparable to Restylane-L. Most adverse events were mild to moderate, consistent with what any patient would expect from any filler: temporary tenderness, swelling, erythema, and bruising at injection points. There were no treatment-related serious adverse events. No delayed-onset nodules occurred with either Evolysse formulation, compared to a 1.4% incidence in the Restylane-L control arm.

Non-inferiority with statistical superiority at multiple timepoints, zero serious adverse events, and reduced product requirement. That is a clinically meaningful package and not a marginal finding.

The two formulations and why the choice matters

Evolysse is available in two formulations and choosing between them is not a matter of preference. It is a matter of anatomy.

Evolysse Form

Higher cohesivity. The gel holds its structure more firmly within tissue, making it suited for deeper placement, more pronounced folds, and areas where structural support is the primary goal. In the pivotal study it demonstrated superiority over Restylane-L at every timepoint throughout the full 12-month period. For patients with more established folds where the tissue needs structural correction rather than gentle softening, Form is the appropriate choice.

Evolysse Smooth

Lower cohesivity. It spreads more readily through tissue, making it better suited for superficial placement, subtler correction, and softer transitions. Appropriate for patients who want natural-looking softening rather than significant volumising. It showed superiority at six and nine months while requiring less product than the comparator, suggesting the Cold-X preservation of HA chain architecture is producing exactly the tissue integration the science predicts.

The decision between them is made at consultation, based on the severity of the fold, the depth at which the product will be placed, and the individual anatomy of the patient. It is not about which one is better in the abstract. It is about which one matches the clinical situation.

The safety reality: what the trial does not tell you

The pivotal study showed no major safety concerns and that is genuinely reassuring. But I want to be direct about something the trial data alone cannot communicate, because I think patients deserve to hear it clearly.

No filler is inherently safe. Safety in filler treatment is a function of technique, anatomical knowledge, and the practitioner's ability to recognise and respond to complications.

The face is not a uniform structure. Blood vessels vary between individuals. The angular artery, the facial artery, the nasolabial fold region itself all contain vascular structures that vary in position and depth between patients. Poor placement can lead to vascular occlusion, which in worst cases causes tissue necrosis or, in extremely rare cases, visual complications. These are not theoretical risks. They are documented in the published literature and I have seen the consequences of inadequate vascular awareness in patients who have come to me following treatment elsewhere.

Clinical trial data tells you what happened in 140 patients treated in controlled conditions by experienced investigators. It does not tell you what happens in all clinical settings, with all practitioners, treating all patient anatomies.

This is why I say, as I do with every injectable treatment: the product matters. The practitioner matters more.

At Juvenology, every filler treatment begins with a full facial assessment, vascular mapping, and an honest discussion about what treatment can and cannot achieve. Hyaluronidase, the enzyme that dissolves HA filler rapidly in an emergency, is always immediately available throughout every treatment. That is not a courtesy. It is a clinical standard that should be non-negotiable at every clinic offering injectable fillers.

Who Evolysse is suited for

Based on the approved indications and the clinical evidence, Evolysse Form and Evolysse Smooth are suited for adults aged 22 and older with moderate to severe nasolabial folds who are seeking natural-looking softening of facial lines rather than dramatic volume addition, and who want subtle, progressive correction with a product that integrates efficiently with tissue.

It is not a treatment for volume loss in the cheeks, lips, or chin. For those concerns, different filler products and approaches are more appropriate and that assessment happens at consultation. For patients whose primary concern is skin quality, hydration, or cellular regeneration rather than fold correction, Profhilo, polynucleotides, or PRP are often more appropriate starting points. For lip enhancement, lip fillers remain the right tool. For structural lifting, PDO threads or HIFU address the underlying tissue laxity that no filler can correct.

Understanding what Evolysse does not do is as important as understanding what it does. That clarity is what the consultation is for.

What this actually means

A decade without a new FDA-approved hyaluronic acid filler is meaningful context. The category is mature. The existing products are good. Getting approval requires demonstrating not just that a new product works, but that it works as well or better than what is already there, in a rigorously controlled study against a well-established comparator.

Evolysse meets that bar. The Cold-X crosslinking rationale is scientifically coherent. The split-face trial is well-designed. The superiority findings are statistically significant and clinically meaningful. The reduced product requirement in the Smooth formulation is particularly interesting because it suggests the technology is doing exactly what it was designed to do at the tissue level.

It is not a revolution. The fundamental principles of good filler treatment, individual assessment, anatomical precision, conservative placement, immediate access to hyaluronidase, haven't changed and won't change regardless of what the product is. But Evolysse is a genuine step forward in formulation science and the data supports that claim.

In cardiac nursing, I learned to welcome advances that are backed by evidence rather than marketing. Evolysse is backed by evidence. What has not changed, and what no product innovation will ever change, is that the outcome ultimately depends on the skill, the anatomy, and the care of the practitioner using it.

Frequently asked questions

What is Evolysse and how is it different from other fillers? Evolysse is an injectable hyaluronic acid filler developed using Cold-X technology, which crosslinks the HA at near-freezing temperatures to better preserve the natural HA chain structure. It received FDA approval in February 2025, the first new HA filler to do so in a decade. In the pivotal clinical trial, both formulations demonstrated non-inferiority and statistical superiority over Restylane-L at multiple timepoints.

How long does Evolysse last? The pivotal study followed patients for 12 months. Evolysse Form demonstrated sustained improvement throughout the full 12-month period. Evolysse Smooth demonstrated superiority at six and nine months. Individual duration varies depending on metabolism, anatomy, treatment volume, and technique.

What is the difference between Evolysse Form and Evolysse Smooth? Form has higher cohesivity and is suited for deeper placement and more structural correction. Smooth has lower cohesivity and is suited for superficial, subtle correction, and demonstrated its results using approximately 20% less product than the comparator. The choice between them is based on individual anatomy and the specific concern being treated, not patient preference.

Is Evolysse available at Juvenology? Yes. Evolysse is part of the treatment options discussed at consultation at Juvenology Clinic, Maidstone. The appropriate product and formulation is determined based on full facial assessment and individual anatomy.

Are dermal fillers safe? Hyaluronic acid fillers have a strong safety record when administered correctly by a qualified, medically trained practitioner. The pivotal Evolysse trial reported no treatment-related serious adverse events and no delayed-onset nodules. As with all injectable treatments, risks exist and are discussed fully at consultation. The MHRA confirms that injectable aesthetic treatments should be performed by appropriately qualified healthcare professionals.

Book your dermal filler consultation at Juvenology, Maidstone

Book a dermal filler consultation at Juvenology Clinic

About the author

Nurse Marina is an aesthetic nurse specialist based in Maidstone, Kent, with over 25 years of nursing experience including cardiac care at KIMS Hospital. She leads Juvenology Clinic with a commitment to anatomical precision, evidence-based practice, and compassionate patient care. Marina is NMC Registered, BACN Member, JCCP Verified, ACE Group Registered, and a Member of the Royal College of Nursing.

From anti-wrinkle injections and dermal fillers to advanced regenerative treatments including polynucleotides, Profhilo, and PRP, Marina combines rigorous medical knowledge with a nurturing, patient-centred approach.

Book a Consultation with Nurse Marina